Interlude Biopharma Co.

15 patents currently held · Updated Nov 15, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Feb 2027

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Dec 9, 2026
The maintenance fee for Larazotide acetate compositions (US 9,051,349) comes due Dec 9, 2026. Unpaid by Jun 9, 2027, it lapses early.
1 fee due Aug 23, 2027
The maintenance fee for Formulations for a tight junction effector (US 9,265,811) comes due Aug 23, 2027. Unpaid by Feb 23, 2028, it lapses early.
1 fee due Sep 8, 2027
The maintenance fee for Materials and Methods for the Treatment of Celiac Disease (US 9,279,807) comes due Sep 8, 2027. Unpaid by Mar 8, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 9,241,969	Method for treating celiac disease In force Ends no later than Feb 9, 2027 · From the USPTO record	In force	Ends no later than Feb 9, 2027	From the USPTO record
US 10,723,763	Use of Tight Junction Antagonists in the Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome In force Ends no later than Oct 23, 2028 · Low confidence	In force	Ends no later than Oct 23, 2028	Low confidence
US 9,051,349	Larazotide acetate compositions In force Term ends Nov 21, 2028 · From the USPTO record	In force	Term ends Nov 21, 2028	From the USPTO record
US 11,149,063	Peptide inhibitors of tight junction permeability In force Term ends May 6, 2029 · From the USPTO record	In force	Term ends May 6, 2029	From the USPTO record
US 9,279,807	Materials and Methods for the Treatment of Celiac Disease In force Term ends Jul 16, 2030 · High confidence	In force	Term ends Jul 16, 2030	High confidence
US 9,265,811	Formulations for a tight junction effector In force (reinstated) Term ends Jun 4, 2031 · From the USPTO record	In force (reinstated)	Term ends Jun 4, 2031	From the USPTO record
US 8,785,374	Inhibitors of mammalian tight junction opening In force Term ends Nov 23, 2031 · From the USPTO record	In force	Term ends Nov 23, 2031	From the USPTO record
US 8,957,032	Inhibition of Gliadin Peptides In force Term ends Dec 6, 2031 · High confidence	In force	Term ends Dec 6, 2031	High confidence
US 9,849,114	Oxymetazoline for the treatment of ano-rectal disorders In force Term ends Apr 24, 2032 · From the USPTO record	In force	Term ends Apr 24, 2032	From the USPTO record
US 11,058,902	Compositions and Methods for Treating Disease Associated with Permeability of Intestinal Epithelium In force Term ends Feb 12, 2038 · High confidence	In force	Term ends Feb 12, 2038	High confidence

10 of 15 patents shown.

Pro members see all 15.

Pro members: see all 15 patents

Also on record, not counted in the 15: 2 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending

List them